clinical trial · NCT05701527

A Study of EBC-129 in Advanced Solid Tumours

EDDC (Experimental Drug Development Centre), A*STAR Research Entities·phase1·recruiting·n = 98

Advanced Solid TumoursEBC-129Pembrolizumab

brief summary

This study will assess the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours

started

Apr 28, 2023

primary completion

Dec 24, 2026

completion

Dec 24, 2026

last updated

Feb 5, 2026

detailed description

This study is a prospective, open label study which is divided into 4 parts.

Part A will be dose escalation segment to identify the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of EBC-129 monotherapy.

Part B will be dose escalation segment to identify the MTD and RP2D of EBC-129 in combination with pembrolizumab.

Part C (dose expansion cohort) will be performed in an expanded cohort of patients with advanced solid malignancies at the RP2D of EBC-129 as a monotherapy identified in the dose escalation segment, Part A.

Part D (Dose Fractionation Cohort) will be performed in patients with advanced solid malignancies with cancer indications that have shown preliminary clinical activity in Part C.

official title

A Phase 1A/B Study To Evaluate The Safety And Tolerability Of EBC-129 As A Single Agent And In Combination With Pembrolizumab In Advanced Solid Tumours

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol